Doylestown, PA, United States of America

Keith Orford

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Keith Orford: Innovator in Cancer Treatment

Introduction

Keith Orford is a notable inventor based in Doylestown, PA (US). He has made significant contributions to the field of cancer treatment through his innovative approaches and patented inventions. With a total of 2 patents, Orford's work focuses on combination therapies that enhance the effectiveness of existing cancer treatments.

Latest Patents

Orford's latest patents include groundbreaking methods for treating cancer or myeloproliferative diseases. One patent details a combination therapy utilizing glutaminase inhibitors alongside anticancer agents such as cabozantinib, crizotinib, and axitinib. This invention addresses the treatment of cancers that are resistant to one or more anticancer agents. Another patent involves novel heterocyclic compounds and their pharmaceutical preparations, which are aimed at treating or preventing cancer.

Career Highlights

Keith Orford is currently associated with Calithera Biosciences, Inc., where he continues to develop innovative solutions for cancer treatment. His work has garnered attention for its potential to improve patient outcomes and provide new avenues for therapy.

Collaborations

Orford collaborates with esteemed colleagues in the field, including Francesco Parlati and Sam H Whiting. Their combined expertise contributes to the advancement of cancer research and treatment methodologies.

Conclusion

In summary, Keith Orford is a dedicated inventor whose work in cancer treatment through innovative combination therapies is making a significant impact. His contributions to the field are paving the way for more effective treatment options for patients facing challenging diagnoses.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…